Perspective Therapeutics, Inc. Common Stock
Key Metrics
- Previous Close
- $3.30
- 52-Week Range
- $1.96 – $6.16
- Market Cap
- $364.14M
- P/E (TTM)
- —
- EPS (TTM)
- -1.29
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 1.12
- PEG Ratio
- —
- Return on Equity
- -39.57%
- Return on Assets
- -22.27%
- Gross Margin
- 0.00%
- Operating Margin
- -36120.99%
- Profit Margin
- 0.00%
- Current Ratio
- 6.61
- Debt/Equity
- 0.01
- Total Debt
- $3.96M
- Free Cash Flow
- $-69.43M
- Revenue Growth
- -72.10%
- Earnings Growth
- —
- Enterprise Value
- $131.23M
Market Snapshot
About
Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company based in Seattle, Washington, specializing in the development of precision targeted alpha therapies for cancer treatment.
The company focuses on discovering and commercializing radiopharmaceuticals that deliver alpha particle radiation directly to cancer cells. Its pipeline includes VMT-α-NET for neuroendocrine tumors, which is in Phase 1/2a trials for patients not previously treated with certain radiopharmaceutical therapies. It is also advancing VMT01, a therapy for metastatic melanoma currently in Phase 1/2a trials, and PSV359, a candidate targeting fibroblast activation protein alpha. Additionally, the company is developing Pluvicto, a beta-emitting therapy for a specific type of prostate cancer.
Perspective Therapeutics operates through clinical development and strategic collaborations. It has a clinical trial collaboration with Bristol Myers Squibb to study the combination of its VMT01 candidate with an existing immunotherapy in melanoma patients. Formerly known as Isoray, Inc., the company changed its name in February 2022 and has been developing its technology platform since its founding in 2004.